[1]Falardeau M. Respect towards people with alzheimer’s disease[J]. Soins Gerontol, 2011(91): 10-12.
[2]Brookmeyer R, Johnson E, Ziegler-Graham K, et al. Forecasting the global burden of Alzheimer’s disease[J]. Alzheimers Dement, 2007, 3(3): 186-191.
[3]Bostrom AM, Van Soest D, Kolewaski B, et al. Nutrition status among residents living in a veterans’ longterm care facility in Western Canada: a pilot study[J]. J Am Med Dir Assoc, 2011, 12(3): 217-225.
[4]Thies W, Bleiler L. 2013 Alzheimer’s disease facts and figures[J]. Alzheimers Dement, 2013, 9(2): 208-245.
[5]Gilbert BJ. Republished: the role of amyloid beta in the pathogenesis of Alzheimer’s disease[J]. Postgrad Med J, 2014, 90(1060): 113-117.
[6]Hollingworth P, Harold D, Jones L, et al. Alzheimer’s disease genetics: current knowledge and future challenges[J]. Int J Geriatr Psychiatry, 2011, 26(8): 793-802.
[7]Anderton BH. Ageing of the brain[J]. Mech Ageing Dev, 2002, 123(7): 811-817.
[8]Imhof A, Kovari E, von Gunten A, et al. Morphological substrates of cognitive decline in nonagenarians and centenarians:a new paradigm[J]? J Neurol Sci, 2007, 257(1-2): 72-79.
[9]Mann DM, Tucker CM, Yates P O. The topographic distribution of senile plaques and neurofibrillary tangles in the brains of non-demented persons of different ages[J]. Neuropathol Appl Neurobiol, 1987, 13(2): 123-139.
[10]Jares P. DNA microarray applications in functional genomics[J]. Ultrastruct Pathol, 2006, 30(3): 209-219.
[11]Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources[J]. Nat Protoc, 2009, 4(1): 44-57.
[12]Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer’s disease[J]. Neurology, 1992, 42(9): 1681-1688.
[13]Bartzokis G. Alzheimer’s disease as homeostatic responses to age-related myelin breakdown[J]. Neurobiol Aging, 2011, 32(8): 1341-1371.
[14]Mann DM, Jones D. Deposition of amyloid (A4) protein within the brains of persons with dementing disorders other than Alzheimer’s disease and Down’s syndrome[J]. Neurosci Lett, 1990, 109(1-2): 68-75.
[15]Grudzien A, Shaw P, Weintraub S, et al. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairmentand early Alzheimer’s disease[J]. Neurobiol Aging, 2007, 28(3): 327-335.
[16]Glenner GG, Wong CW. Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein[J]. Biochem Biophys Res Commun, 1984, 122(3): 1131-1135.
[17]GarciaSierra F, Hauw JJ, Duyckaerts C, et al. The extent of neurofibrillary pathology in perforant pathway neurons is the key determinant of dementia in the very old[J]. Acta Neuropathol, 2000, 100(1): 29-35.
[18]Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly[J]. J Neuropathol Exp Neurol, 2003, 62(11): 1087-1095.
[19]Armstrong RA. What causes Alzheimer’s disease[J]? Folia Neuropathol, 2013, 51(3): 169-188.
[20]Kovacs T. Therapy of Alzheimer disease[J]. Neuropsychopharmacol Hung, 2009, 11(1): 27-33.
[21]Chen Y, Qin LH, Chen XP, et al. Interfering effect and prohable mechanism of neregulin on experimental dementia model in rats [J]. Acta Anatomica Sinica, 2010, 41(5): 666-669. (in Chinese)
陈燕,秦丽华,陈希平,等. 神经调节素对实验性痴呆大鼠的干预作用和可能机制[J]. 解剖学报, 2010,41(5): 666-669. |